A Phase II Study of the Feasibility to Derive Autologous Vaccine (HSPPC-96) From Tumor Tissue for Clinical Administration in Patients With Resectable Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2016
At a glance
- Drugs Vitespen (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Mar 2009 Actual end date (1 Nov 2007) added as reported by ClinicalTrials.gov.
- 06 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 May 2008 A poster presentation will be made at the Annual Meeting of the American Society of Clinical Oncology in May-June.